Stockscreener 앱 받기
6.75
2.88%
-0.20
시간 외 거래:
6.65
-0.10
-1.48%
전일 마감가:
$6.95
열려 있는:
$6.94
하루 거래량:
142.06K
Relative Volume:
1.21
시가총액:
$34.65M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-4.50
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
-33.43%
1개월 성능:
-7.22%
6개월 성능:
-57.59%
1년 성능:
-86.43%
1일 변동 폭
$6.58
$7.04
1주일 범위
$6.55
$8.645
52주 변동 폭
$6.4725
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.75 | 34.65M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Published on: 2025-07-30 03:04:39 - metal.it
Published on: 2025-07-29 23:14:19 - metal.it
Will Mersana Therapeutics Inc. benefit from macro trendsGrowth Based Investment Plan Guidance Highlighted - metal.it
Will Mersana Therapeutics Inc. stock split in the near futureBreakout Stocks Insights To Watch Now - jammulinksnews.com
Is Mersana Therapeutics Inc. a Top Dividend Stock to Watch in 2025Watchlist for Low Risk High Return Stocks Updated - metal.it
What is Mersana Therapeutics Inc. company’s growth strategyUnmatched market performance - jammulinksnews.com
Does Mersana Therapeutics Inc. stock perform well during market downturnsBreakthrough capital growth - jammulinksnews.com
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Exceptional stock performance - jammulinksnews.com
What are the latest earnings results for Mersana Therapeutics Inc.Maximize returns with disciplined trading approaches - jammulinksnews.com
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - metal.it
How does Mersana Therapeutics Inc. generate profit in a changing economyBuild a winning portfolio with smart picks - jammulinksnews.com
How Mersana Therapeutics Inc. stock performs during market volatilityTop Growth Low Risk Stocks - metal.it
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey
What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq
Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com Australia
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan By Investing.com - Investing.com South Africa
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday By Investing.com - Investing.com South Africa
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus
Mersana Therapeutics Announces Reverse Stock Split - TipRanks
Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com India
Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com Australia
Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.40%
자본화:
|
볼륨(24시간):